EHA 2015 | Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Name: Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
Uploaded: 2015-06-12T00:00:00.000Z
Duration: 3 min 12 s
Description: At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).

Giuseppe Saglio • 12 Jun 2015

EHA 2015

Chronic Myeloid Leukemia Dasatinib Nilotinib

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).